ArticleFrontiers in oncology2022

Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel-based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancer.

Xingsheng Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.